glp-1 news today 2025 november 6 Agonists Market Report 2025-2033, By Product, Molecule, and Geo Novo Nordisk, Lilly strike deal

The gap between diet-only tools and prescription GLP-1 drugs isnt going away

The multifaceted impact of IF on the gut microbiome axis highlights its potential as a sustainable, non-pharmacological intervention for managing gastrointestinal and metabolic disorders [80,81,82] (Table 3)

Msimbira LA, Smith DL

Results at 72 weeks were striking: 5mg dose: 15.0% average weight loss 10mg dose: 19.5% average weight loss 15mg dose: 20.9% average weight loss Placebo: 3.1% average weight loss At the highest dose, 36.2% of participants lost 25% or more of their body weight

Chung SD, Chen CH, Hung SH, Lin HC, Wang LH

doi: 10.1007/s00415-013-6878-2